Neurotoxicity of 5-fluorouracil;Neurotoxizität von 5-fluorouracil

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 39, 2002, Pages 2011-2014

  Sucker, Christoph ^a   Lambers, C ^a   Stockschlader M ^a   Dolken G ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ARTICLE; CHEMOTHERAPY; CLINICAL FEATURE; HUMAN; NEUROTOXICITY; PATHOGENESIS;

ANTIMETABOLITES, ANTINEOPLASTIC; CEREBELLAR ATAXIA; FLUOROURACIL; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES;

EID: 18644380795     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34361     Document Type: Article

References (34)

1. Akiba T, Okeda R, Tajima T. Metabolites of 5-fluorouracil, α-fluoro-β-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture. Acta Neuropathol 1996; 92: 8-13
2. Aksoy M, Basu TK, Brient J, Dickerson JWT. Thiamine status of patients treated with drug combinations containing 5-fluorouracil. Eur J Cancer 1980; 16: 1041-1045
3. Boileau G, Piro AJ, Lahiri SR et al. Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy. Cancer Chemother Rep 1971; 55: 595-598
4. Bourke RS, West CR, Chheda G et al. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid following intravenous injection in a primate. Cancer Res 1973; 33: 1735
5. Bygrave HA, Geh JI, Jani Y, Glynne-Jones R. Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature. Clin Oncol 1998; 10: 334-336
6. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 1998; 12: 23-27
7. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 1988; 81: 47-51
8. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacogenetics 1989; 16: 215-237
9. Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248-2253
10. Fassas ABT, Gattani AM, Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest 1994; 12: 379-383
11. Fleming RA, Milano G, Thyss A et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer 1992; 52: 2899-2902
12. Gottlieb JA, Luce JK. Cerebellar ataxia with weekly 5-fluorouracil administration (letter). Lancet 1971; i: 138-139
13. Greenwald ES. Organic mental changes with fluorouracil therapy. J Am Med Assoc 1976; 235: 248-249
14. Grem JL. 5-Fluoropyrimidines. 2nd ed (Hrsg). Philadelphia: Lippinscott-Raven, In: Chabner BA, Longo DL (eds.), Cancer chemotherapy and biotherapy: principles and practice. 1996: 149-211
15. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991; 68: 499-501
16. Hook CC, Kimmel DW, Kvols LK et al. Multifocal inflammatory leukencephalopathy with 5-fluorouracil and levamisol. Ann Neurol 1992; 31: 262-267
17. Kliche KO, Schalhorn A, Höffken K. Nachweis von DPD-Exon-14-Skipping vor 5-Fluorouracil-Behandlung? Dtsch Med Wochenschr 2002; 127: 463-464
18. Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. Arch Neurol 1970; 23: 155-160
19. Leichman L, Brown T, Poplin B. Symptomatic, radiologic, and pathologic changes in the central nervous system (CNS) associated with 5-fluorouracil (5-FU) and levamisole (LEV) therapy (abstract). Proc Am Soc Clin Oncol 1993; 12: 198
20. Luppi G, Zoboli A,0 Barbieri F, Crisi G, Piccinini L, Silingardi V. Multifocal leukencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. Ann Oncol 1996; 7: 412-415
21. Mehta VK, Poen JC, Ford JM et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001; 24: 155-159
22. Meropol NJ, Creaven PJ, Petrelli NJ et al. Seizures associated with leucovorin administration in cancer patients. JNCI 1995; 87: 56-58
23. Milano G, Etienne MC. Fluorinated pyrimidines 289-300; Baltimore, Williams & Wilkins, in Grochow LB, Ames MM (eds): clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. 1998
24. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79: 627-630
25. Milano G, McLeod HL. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 2000; 36: 37-42
26. Moertel CG, Reitmeir RJ, Bolton CF et al. Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964; 41: 15-18
27. Ridge SA, Sludden J, Wei X et al. Dihydropyridine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 1998; 77: 497-500
28. Riehl JL, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964; 14: 254
29. Saletti P, Pagani O, Sessa C, Goldhirsch A. Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration. Ann Oncol 1996; 7: 2
30. Sloan JA, Goldberg RM, Sargent DJ et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002; 20: 1491-1498
31. Soukop M, Kalman KC. Thiamine status in cancer patients and the effect of 5-fluorouracil therapy (abstract). Br J Cancer 1978; 38: 180
32. Sucker C, Scheffold N, Cyran J. Koronarer Vasospasmus unter Chemotherapie mit 5-Fluorouracil. Dtsch Med Wochenschr 2001; 46: 1300
33. Wei X, McLeod HL, McMurrough J et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98: 610-615
34. Yeh KH, Cheng AL. Acute confusion induced by high-dose infusion of 5-fluorouracil and folinic acid. J Formos Med Assoc 1994; 93: 721-723